A new study published in the peer-reviewed journal, Dysphagia, suggests that the proportion of seniors with swallowing problems in the U.S. is expected to top 20% by 2030 from 15% currently. “Dysphagia has...
Titan Pharmaceuticals (NASDAQ:TTNP) has entered into an amendment of an earlier asset purchase, supply and support agreement with L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A., which allowed Molteni...
Closely-held Vasomune Therapeutics and AnGes (Tokyo, TYO:4563) signed a global co-development agreement for the development and commercialization of therapeutics treating diseases associated with blood vessel...
PharmaJet and Mundipharma have inked an exclusive partnership to market and distribute PharmaJet’s Tropis and Stratis needle-free drug-delivery devices to more than 120 markets around the world. The devices are designed...
Synexus, a leading global network of research sites, is collaborating with the University of Exeter in the UK to launch one of the largest, registry-based research initiatives in the U.S. to help understand how healthy...
Israel-based Respinova has won the second grant offered by Chiesi Spain and Richi Entrepreneurs to promote an innovative project that directly impacts treatment and quality of life of patients with chronic obstructive...
Imagin Medical (CSE:IME; OTCQB:IMEXF) reported favorable results in a 10-subject investigator-sponsored research study at the University of Rochester Medical Center (URMC) using the i/Blue Imaging System, an important...
Profound Medical (TSXV:PRN; OTCQX:PRFMF) has received final approval to list its common shares on the Toronto Stock Exchange, effective at the opening on July 13, 2018. The stock will continue to trade under the symbol...
A study published in the scientific journal, npj Parkinson’s Disease, estimates that 930,000 people in the U.S. will be living with the disease by 2020, further increasing to 1.2 million people by 2030. “Our...
ASLAN Pharmaceuticals (TPEx:6497; NASDAQ:ASLN) has applied to the Singapore Health Sciences Authority to conduct a Phase 1 clinical trial of ASLAN004. The single ascending dose study will recruit healthy volunteers and...
Closely-held Urotronic of Plymouth, MN has received a license to begin treating urethral strictures with its Optilume drug-coated balloon (DCB) catheter in Canada. “We are quite excited to see this come to market,” Dr...
Aquinox Pharmaceuticals (NASDAQ:AQXP) announced that the Phase 3 LEADERSHIP 301 clinical trial, evaluating once-daily, oral rosiptor (AQX-1125) for the treatment of interstitial cystitis/bladder pain syndrome, failed to...
Ortho Regenerative Technologies (CSE:ORTH) reported positive outcomes data from a study examining its Ortho-R technology in the biologic repair of rotator cuff injuries. Conducted by researchers from Montreal’s École...
Titan Pharmaceuticals (NASDAQ:TTNP) and Braeburn agreed to terminate a December 2012 license agreement, which granted Braeburn exclusive rights to commercialize Probuphine in the U.S. and Canada. Under the...
Ortho Regenerative Technologies (CSE:ORTH) received a notice of allowance from the European Patent Office for a patent entitled, “Soluble Physiological Chitosan Formulations Combined with Platelet-Rich Plasma...
Cara Therapeutics (NASDAQ:CARA) licensed worldwide rights, except in the U.S., Japan and South Korea, to commercialize KORSUVA injection for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in...
Closely-held Beta Bionics received FDA approval to begin home-use clinical studies of an autonomous bionic pancreas that employs artificial intelligence to vary hormone doses in adults and children with Type 1 diabetes...
Nabriva Therapeutics (NASDAQ:NBRV) reported positive top-line results from its LEAP 2 clinical trial, the second of two global, Phase 3 clinical trials of its antibiotic, lefamulin. LEAP 2 evaluated the safety and...
Closely-held Tear Film Innovations completed an $8.5-million Series B preferred stock round led by Visionary Ventures Fund and Bluestem Capital. “This successful funding round completes the capitalization for our growth...
Profound Medical (TSXV:PRN; OTCQX:PRFMF) presented positive initial data from its TACT pivotal study with its TULSA-PRO ablation device at the American Urological Association (AUA) annual meeting in San Francisco. The...
Closely-held CellAegis announced completion of patient enrollment in a large investigator sponsored trial to further assess the efficacy of remote ischemic conditioning (RIC) using its autoRIC device to deliver the RIC...
Canopy Growth (TSX:WEED) has agreed to acquire the shares it doesn’t already own in Canopy Health Innovations (CHI) and CHI’s subsidiary, Canopy Animal Health, bringing its affiliated research arm fully into the...